> ## Content Index
> Fetch the complete content index at: https://www.theinvestorsociety.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Warhound: US$200M at US$1.2B to End U.S. Reliance on European Military Dogs
- URL: https://www.theinvestorsociety.com/warhound-us-200m-at-us-1-2b-to-end-u-s-reliance-on-european-military-dogs/
- Published: 2026-10-23T18:15:22.000Z
- Updated: 2026-10-23T18:15:22.000Z
- Author: The Editor

Warhound, a defense biotech startup that genetically engineers working dogs, came out of stealth on October 22, 2026, with US$200 million in funding at a US$1.2 billion valuation, according to TechCrunch. The round was backed by In-Q-Tel, the nonprofit venture arm that invests on behalf of U.S. intelligence agencies, along with Sequoia Capital and 8VC. The company was conceived by Ben Lamm, co-founder and CEO of de-extinction company Colossal Biosciences, and Palmer Luckey, founder of defense contractor Anduril. Lamm said Luckey is a partner with no equity, while Colossal owns a stake and licenses its technology. Gadget Review reports that Warhound is based in Texas and led by CEO David Spirk, a former chief data officer at the U.S. Department of Defense.

The company starts with cell lines from Belgian Malinois and German Shepherds, stores them in a biobank and then edits genes to improve health, longevity, speed, agility and sense of smell. Viagen, a Colossal-owned company, will clone the dogs, and Anduril will supply gear such as protective vests and goggles to help dogs and handlers coordinate in the field. The American Humane Society will guide certification of the training program. The first batch is about to be cloned, with births expected early next year and service in about two years, Lamm said. Pricing has not been set. The pitch is supply security: more than 80% of U.S. military working dogs come from Europe, and fewer than half of them are fit for service, according to the company.

## Market Context

Warhound is the first commercial spin-off aimed at defense from Colossal, which was valued at US$10.2 billion in January 2025 and drew global attention that year with its "dire wolf" project, gray wolves edited to resemble the extinct species. Colossal has also been applying AI to identify and edit genes. Warhound turns that toolkit toward a buyer with deep pockets and a clear supply problem: the Pentagon, police departments and emergency response teams.

The deal also reflects how much private capital is flowing into defense technology. Anduril, valued at more than US$30 billion in 2025, has made defense a mainstream venture category, and In-Q-Tel's participation signals early interest from the national security community. A US$200 million first round at a US$1.2 billion valuation, before a single dog has been born, is unusually large for a company at this stage.

## Key Signal

> "On top of the dog, not in the dog." Ben Lamm, co-founder and CEO of Colossal Biosciences, on how Anduril's technology will be added to Warhound's dogs

## Regional Relevance

For the United States, Warhound frames military dogs as a supply chain issue, similar to chips or critical minerals. Relying on European breeders for most of the military's working dogs leaves the country exposed to delays and quality gaps. If the model works, it would bring breeding home and give U.S. agencies more control over the health and abilities of the dogs they deploy for bomb detection and search work.

For Texas, the launch adds to a growing cluster of biotech and defense companies, anchored by Dallas-based Colossal. For Latin America, where police and armed forces rely heavily on detection dogs for drug and explosives searches, the technology could eventually be relevant, but Warhound has only named U.S. customers so far and has not set a price.

## The Other Side

**Is the science proven?** No engineered dog has been born yet. Improving health through cloning and genetic screening is a near-term goal, but editing for a sharper sense of smell is still a future idea. Results in working conditions will take years to measure.

**Will regulators and the public accept gene-edited service animals?** Cloning and gene editing in animals raise welfare and ethical questions. In the U.S., the FDA oversees intentional genetic changes in animals, and the announcement does not explain how Warhound plans to handle that review. American Humane's role covers training certification, not the genetic work itself.

**What does the valuation rest on?** Warhound has no product on the market, no published pricing and no announced government contract. Lamm said the company has briefed many government groups, but briefings are not orders. Military procurement is slow, and the valuation assumes that demand will turn into sales.

## Sources & Transparency

- [Warhound raises $200M to engineer war dogs and arm them with Anduril gear](https://techcrunch.com/2026/10/22/ben-lamm-raises-200m-for-warhound-to-engineer-war-dogs-and-arm-them-with-anduril-gear/?ref=theinvestorsociety.com)
- [Warhound Raises $200 Million to Clone Elite Military Dogs](https://www.gadgetreview.com/warhound-raises-200-million-to-clone-elite-military-dogs?ref=theinvestorsociety.com)
- [Genetically Engineered War Dogs for 134 Pound Cyborg Dire Wolves Now](https://www.nextbigfuture.com/2026/10/genetically-engineered-war-dogs-that-wear-cyber-gear.html?ref=theinvestorsociety.com)
- [Warhound launches with $200 million seed round to supply genetically screened military dogs](https://tradersunion.com/news/billionaires/show/3936635-warhound-military-dogs-seed-round/?ref=theinvestorsociety.com)
- [Warhound Launches With $200 Million to Build Genetically Engineered Military Dogs](https://finance.biggo.com/news/6ccec038-851b-4c2e-91a8-aa1d03819d8a?ref=theinvestorsociety.com)